Extended Data Table 3 Number of HGG recurrences at time of CAN-3110 accrual/HSV1 and HSV2 serology and blood biodistribution

From: Clinical trial links oncolytic immunoactivation to survival in glioblastoma

  1. (related to Sub-headings, Safety of CAN-3110 in rHGG/rGBM patients and to Sub-Heading, HSV1 serology predicts efficacy)
  2. *One subject in cohort 9 (subject 042) was re-treated as part of cohort 10 (subject 054). See explanation in Supplemental Text. †Multifocal staining pattern could be caused by tissue fragmentation.
Back to article page